Currently, there is a paucity of data regarding outcomes of transplantation in patients with previous hematologic malignancies (HMs); therefore, its safety continues to be questioned. Data from the Israel Penn International Transplant Tumor Registry (IPITTR) reported a 21% overall malignant recurrence rate in 1137 patients, 49 (4.3%) of which had HMs treated prior to or at the time of RT. 3 This leads to a recommendation for a minimum waiting period prior to RT of 2 to 5 years post-remission depending on the etiology of the cancer. 2, 3 However, these recommendations are based on old reports and do not take into consideration recent advancements in the management of HMs. In addition, the impact of transplantation on de novo malignancy and overall patient survival in this patient population remains unknown. 5 As a result, this study was undertaken to describe patient and allograft outcomes for patients receiving RT with previous HMs in the modern era.
Methods
This was a single center, IRB approved, retrospective review of adult patients (⩾18 years old) who received a living or deceased RT at a large, academic hospital between January 2009 and January 2016. Patients were included if they had a prior diagnosis of multiple myeloma (MM), leukemia, lymphoma, light chain deposition disease, systemic light chain (AL) amyloidosis, or myeloproliferative disorder including monoclonal gammopathy of undetermined significance (MGUS) during the specified time frame.
All clinical and baseline demographic data were collected via the electronic medical record (Epic © ) in accordance with local institutional review board guidelines. All patients were followed for a minimum of 3 years from the date of RT for data collection purposes. The primary objective of this study was to describe the incidence of new or recurrent malignancy post-RT in patients with previous HMs. Key secondary endpoints included 3 year rates of patient and allograft survival, acute biopsy-proven rejection, and 1-year incidence of infections requiring hospitalization. Descriptive statistics were used to summarize baseline characteristics and patient and allograft outcomes.
Results
Eight patients were identified for inclusion in the review. Six patients received prior chemotherapy and five had a previous hematopoietic stem cell transplant (HSCT). Median age at time of RT was 59 (53-62) years and median time from remission to RT was 2.6 years (Table 1) .
Immunosuppression
Four patients (50%) received induction with rabbit antithymocyte globulin (rATG). One patient with a history of marginal zone lymphoma (MZL) also received rituximab 375 mg/m 2 and intravenous immunoglobulin 2 g/kg for donor-specific antibodies (DSAs) 8 days post-RT. The remaining four patients (50%) received induction with an interleukin-2 receptor antagonist (IL-2RA). All patients were initiated on tacrolimus and mycophenolate, and five patients were discharged on maintenance corticosteroids.
New malignancies at 3-years
Three patients (38%) developed new malignancies within 3 years following RT (Table 2) . One patient with a history of MM developed pancreatic cancer 2.3 years post-RT and died due to cancer-related complications with a functioning allograft. Another patient with a history of pre-B cell acute lymphocytic leukemia (ALL) with multiple cytogenetic abnormalities developed acute myeloid leukemia (AML) 2 years post-RT but was alive 3 years post-RT with a functioning allograft. Both patients were treated with chemotherapy and HSCT prior to RT. The patient with MZL developed undifferentiated non-Hodgkin's lymphoma (NHL) 2.9 years post-RT and was alive 3 years post-RT with a functioning allograft.
Recurrent malignancies at 3-years
There was concern for recurrent malignancies in two out of eight (25%) patients by 3 years following RT, both treated with chemotherapy and HSCT prior to RT (Table  2) . One patient with a history of MM developed an increase in serum free light chains with a rising kappa and kappa/ lambda ratio 2.5 years post-RT. Another patient with AL amyloidosis developed elevated kappa free light chain levels 1.7 years post-RT. Bone marrow biopsy revealed 5%-10% plasma cells but was ultimately inconclusive for recurrence. Both patients were alive with functioning allografts and had not received chemotherapy at 3-year follow-up. However, patient 3 experienced subsequent relapse of MM 3.9 years post-RT.
1-and 3-year patient and graft survival
Patient and graft survival was 100% and 87% at 1 year, and 87% and 75% at 3 years, respectively. Mean serum creatinine was 1.5 mg/dL in six patients with surviving allografts at 3 years. One patient had primary non-function, and one patient died due to cancer-related complications within 3 years following RT. The patient with de novo AML died 3.1 years after RT.
Acute rejections and serious infections
Among the 8 patients, there was 1 case of biopsy-proven rejection (suspected acute antibody-mediated rejection in the patient with primary non-function) within 3 years post-RT. Three patients (38%), all of whom received rATG, developed infections requiring hospitalization during the first year following RT ( 
Discussion
Historically transplant centers have considered many HMs, including MM and AL amyloidosis, to be an absolute contraindication to RT due to poor response rates to treatment and early disease relapse. 2, 6, 7 However, advances in the treatment of HMs have resulted in improved cure rates and prolonged survival, raising the question of these patients' candidacy for RT. 8 Our experience suggests that select patients with prior HM can be transplanted with reasonable short-term outcomes but with an increased risk for de novo cancers which may portend a poor prognosis. Among our cohort, patients with recurrence of their original disease were managed medically without sacrificing graft function, while two out of three patients with de novo malignancy succumbed to their cancers within 4 years. These risks should be weighed against the significant morbidity and mortality associated with chronic hemodialysis and should be addressed through shared decision-making involving patients, hematologists, and transplant providers. Risk stratification should also take into account that HMs are a heterogeneous group of disorders with significant variability in recurrence and prognosis. In the IPITTR analysis, 12 patients had a diagnosis of MM prior to transplantation, 8 out of 12 (67%) of which developed recurrence of their malignancy (time from transplant to recurrence not reported). 3 Advances in MM management have extended overall patient survival, with low-risk patients demonstrating median survivals longer than 5 years. 6, 7 However, a majority of patients will still relapse within 3 years from diagnosis and it remains unclear whether immunosuppression after RT accelerates this course. 9 Le et al. recently described the outcome of RT in four patients with a history of MM previously treated with chemotherapy and HSCT who underwent RT a median of 42.5 months after remission. One patient experienced recurrence of MM at 6 months following RT, but subsequently re-established disease control. 6 Shah et al. described outcomes in five patients with a history of MM previously treated with chemotherapy and HSCT. Two (40%) patients experienced MM relapse 6 and 16 months following RT. Both patients died at 55 and 48 months after RT. 10 Table 3 summarizes published cases of renal transplantation in patients with previous MM or AL amyloidosis. In our three patients with MM, one developed recurrence while another developed de novo pancreatic cancer within 4-year post-RT. Whether the history of MM contributed to the risk for pancreatic cancer remains unclear.
AL amyloidosis was present in two of our patients, one of whom subsequently developed serologic disease recurrence at 1.7 years post-RT. Both patients were alive with functioning allografts at 3 years. Hermann et al. found similar overall survival among AL patients who received HSCT after RT (n = 8), HSCT prior to RT (n = 6), and conventional chemotherapy prior to RT (n = 5). Recurrent disease was found in 3 out of 19 (16%) patients, with no patient or graft loss due to recurrent amyloid. 13 Sattianayagan et al. reported the outcomes of 22 AL patients who received RTs, 19 of which received chemotherapy or HSCT prior to RT. Recurrent disease was found in 5 (23%) patients after a median of 5.6 years post-RT (Table 3 ). 14 Overall, this experience suggests that although AL recurrence is relatively common post-RT, it is rarely directly fatal to the allograft.
We also included two patients who did not receive chemotherapy for HM prior to transplant. One had early stage MZL, an indolent type of cancer, and one patient had MGUS. The patient with marginal cell lymphoma received rituximab at the time of transplant for DSA and because it is a treatment for MZL. Although MGUS is not a true malignancy, it is a premalignant condition that can progress to MM or other types of HM. In our series, both patients had excellent outcomes after transplant.
In our study, three out of eight (38%) patients were diagnosed with new cancers post-RT, and recurrent HMs were suspected in two out of eight (25%) patients. Of note, four out of five of these patients received chemotherapy and HSCT pre-RT. It is possible that the HSCT was simply a marker of more aggressive baseline disease resulting in an increased risk for post-transplant recurrence. In addition, these patients had been heavily immunosuppressed, which may have contributed to impaired T-cell surveillance mechanisms post-transplantation and an increased risk for de novo malignancy. This hypothesis has been suggested by several studies which reported the risk for secondary malignant neoplasms after HSCT to be 4-to 11-fold higher than that of the general population. 16 Previous reports have also found an association between total cumulative immunosuppression and malignant risk. In particular, lymphocyte depleting agents used for induction or rejection have been associated with higher rates of post-transplant lymphoproliferative disorders but not necessarily solid tumors. 17 In our case series, acute rejection rates were low regardless of induction agent, and all three patients who developed serious infections received rATG, raising the question of whether lymphocyte depleting induction is necessary in these immunologically complex patients who have often already received multiple lines of cytotoxic chemotherapy prior to RT. With regard to maintenance immunosuppression, there have been higher rates of malignancy retrospectively reported with tacrolimus-based regimens compared to cyclosporine, and azathioprine-based regimens relative to mycophenolate. 18, 19 Mammalian target of rapamycin (mTOR) inhibitors have been associated with reduced rates of solid tumors but have not shown a benefit in overall survival. 20 All of our patients received tacrolimus and mycophenolate and none were converted to an mTOR inhibitor post-RT. In order to decrease global immunosuppression, minimization strategies including conversion to mTOR inhibitors may warrant further investigation specifically in patients with HMs. There were several limitations to this study. This was a single center retrospective study in a heterogeneous population of patients with HMs. Most of our patients' cancers were treated at outside centers; therefore, we did not have access to every detail regarding histology and treatment of their malignancies. Finally, a median follow-up of 3 years post-RT may not have been sufficient time to allow for de novo or recurrent malignancy to manifest.
Conclusion
Our study suggests that RT can be successfully performed in carefully selected patients with prior HM albeit with close serologic monitoring. Our experience also suggests that de novo rather than recurrent malignancy may be associated with poorer prognosis post-RT. In patients who have been heavily previously immunosuppressed with chemotherapy and HSCT, the risk for future malignancy should be weighed against the expected survival on hemodialysis and should include evaluation by a hematologist. These patients may benefit from avoiding lymphocyte depleting induction and minimizing maintenance immunosuppression, although the optimal management strategy remains controversial. Future studies should seek to clarify the optimal time after remission to perform RT, long-term outcomes in this population, and the safest immunosuppressive protocol in these immunologically complex patients.
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